Pharmacy Screening Program Triples Scope for Heart Risk
NCPA, CPESN and Bristol Myers Squibb expand a pharmacist-led stroke and heart disease screening program into six more states.
Updated on Nov. 18, 2026 in Heart Disease

Live Poll
Would you trust your local pharmacist to screen you for heart disease risk?
The National Community Pharmacists Association, CPESN and Bristol Myers Squibb are expanding a stroke and heart disease screening program for pharmacists, tripling its scope. Phase 2 will add up to 50 pharmacies across six more states to screen 15,000 patients.
Why it matters
Phase 1 pharmacy teams identified nearly 10,000 at-risk patients and referred 81% of those with abnormal heart rhythm to a physician, showing pharmacies can serve as a screening point for cardiovascular risk. Expansion tests whether that model holds across a wider set of states and pharmacies.
The Phase 1 screening program identified 400 patients with abnormal heart rhythm, and 81% of them were referred to a physician. Results from the six-state, six-month pilot do not yet show whether Phase 2 will produce similar referral rates.
The players
National Community Pharmacists Association (NCPA)
The NCPA is a national trade association representing independent community pharmacies and their owners across the United States.
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that supports the program as its funder.
The details
Pharmacists screen and counsel patients for cardiovascular risk, while pharmacy technicians cross-trained as community health workers engage at-risk patients and connect them with social services. Phase 2 will run for six months and track health outcomes for patients identified at risk in Phase 1.
Timeline
Phase 1 ran for six months at 25 pharmacies in Alabama, Arkansas, Kentucky, Louisiana, Mississippi and Missouri.
Phase 2 will run for six months, adding up to 50 pharmacies across six more states, including Florida.
Health Landscape
The expansion builds on CPESN's network of community pharmacies, which has been used to deliver services beyond dispensing medications. Pharmacy-based screening for heart disease and stroke risk is a way to reach patients in the Stroke Belt, where cardiovascular disease is especially prevalent.
Patients who visit participating pharmacies may be screened for cardiovascular risk and, if flagged, referred to a physician or connected with social services. The program's Phase 1 results suggest a routine pharmacy visit can prompt follow-up care for stroke and heart rhythm concerns.
The takeaway
Pharmacies can serve as an accessible point for cardiovascular risk screening, and asking your pharmacist about heart and stroke risk is a practical step. Watch whether Phase 2 results confirm the referral patterns seen in Phase 1.
What happens next
Phase 2 will run for six months at up to 50 pharmacies across six additional states, with health outcomes for Phase 1 at-risk patients tracked during that period.
Further reading
Explore more on Heart Disease and related cardiovascular screening efforts across the country.
Source note: This article includes information reported by Drug Store News.
Live Poll
Would you trust your local pharmacist to screen you for heart disease risk?










